Kite Pharma was off by 15% in morning trading after it announced the death of a patient in late April of cerebral edema—the very same fatal outcome that beset rival Juno’s Rocket trial, killing five ...
The death rattled Kite investors because death from brain swelling, or cerebral edema, is the same severe toxic event that scuttled a competing CAR-T therapy from Juno Therapeutics. The patient death ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback